Research map: Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma?

Back to the article

Papers in this map

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma · S. Vincent Rajkumar · 2014 · 5044 citations · Cited by this paper
  2. Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think? · 2026 · Related
  3. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma · Antonio Pierangelo Palumbo · 2016 · 1540 citations · Cited by this paper
  4. Challenges faced by women and girls with hemophilia/Carriers: an expert call for closing the diagnosis gap · 2026 · Related
  5. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors · Michel de Weers · 2010 · 1045 citations · Cited by this paper
  6. Social challenges and support needs of patients with hemophilia in Pakistan: a qualitative exploratory study · 2026 · Related
  7. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study · Philippe Moreau · 2019 · 977 citations · Cited by this paper
  8. Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs · 2026 · Related
  9. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma · Jakub Krejcik · 2016 · 957 citations · Cited by this paper
  10. A Review of Disparities in Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma · 2026 · Related
  11. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma · Robert A. Kyle · 2007 · 932 citations · Cited by this paper
  12. Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison · 2026 · Related
  13. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma · Sagar Lonial · 2019 · 912 citations · Cited by this paper
  14. An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor) · 2026 · Related
  15. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† · Meletios Athanasios Dimopoulos · 2021 · 849 citations · Cited by this paper
  16. Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing · 2026 · Related
  17. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells · Ernesto Pérez Persona · 2007 · 588 citations · Cited by this paper
  18. Apparent plateaus during iron chelation in transfusion-dependent β-thalassemia: interpretation and clinical implications · 2026 · Related
  19. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma · Pieter Sonneveld · 2023 · 584 citations · Cited by this paper
  20. Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention · 2026 · Related
  21. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma · Marije B. Overdijk · 2015 · 518 citations · Cited by this paper
  22. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma · Angela Dispenzieri · 2007 · 437 citations · Cited by this paper
  23. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial · Meletios Athanasios Dimopoulos · 2021 · 343 citations · Cited by this paper
  24. Multiple myeloma · Florent Malard · 2024 · 327 citations · Cited by this paper
  25. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria · Arjun Lakshman · 2018 · 307 citations · Cited by this paper
  26. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) · María‐Victoria Mateos · 2020 · 294 citations · Cited by this paper
  27. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial · María‐Victoria Mateos · 2020 · 252 citations · Cited by this paper
  28. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma · S. Vincent Rajkumar · 2013 · 241 citations · Cited by this paper
  29. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma · Tineke Casneuf · 2017 · 233 citations · Cited by this paper
  30. EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma · Meletios Athanasios Dimopoulos · 2025 · 157 citations · Cited by this paper
  31. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial · Saad Z. Usmani · 2025 · 145 citations · Cited by this paper
  32. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial · Meletios Athanasios Dimopoulos · 2023 · 139 citations · Cited by this paper
  33. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma · Meletios Athanasios Dimopoulos · 2024 · 120 citations · Cited by this paper
  34. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials · Saad Z. Usmani · 2020 · 111 citations · Cited by this paper
  35. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) · Ola Landgren · 2020 · 105 citations · Cited by this paper
  36. Prevalence of smoldering multiple myeloma based on nationwide screening · Sigrún Þorsteinsdóttir · 2023 · 94 citations · Cited by this paper
  37. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma · Luciano J. Costa · 2025 · 89 citations · Cited by this paper
  38. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma · Ajay K. Nooka · 2018 · 86 citations · Cited by this paper
  39. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes · Thierry T.F. Facon · 2025 · 61 citations · Cited by this paper

Source: OpenAlex (CC0)